Author + information
Myeloperoxidase (MPO) is a biomarker of inflammation and oxidative stress produced by neutrophils, monocytes, and endothelial cells1. MPO levels increase in patients with heart failure. Increased MPO is associated with prognosis and left ventricular function in these patients. Heart-type fatty acid-binding protein (H-FABP) is a low molecular weight (15 kD) cytoplasmic protein, whose role is intracellular transportation of free fatty acid in the cardiomyocyte.H-FABP is widely used to evaluate ongoing myocardial damage.
The aim of the present study was to investigate the relationship between MPO and myocardial damage.
We studied 42 consecutive patients with chronic heart failure. Serum H-FABP and MPO levels were measured by ELISA kits. Routine biochemical and clinical parameters were recorded. Echocardiographic examinations were performed in all patients.
Mean age of study groupwas 67±12 years. MPO and H-FABP levels were measured as 255±227 (ng/mL) and 60.6±48.5 (ng/mL) respectively in the study group. Positive correlation was found between H-FABP and MPO (r=0.61 p=0.0001) (Figure 1). In multiple linear regression analysis, it was found that the age (β=-0.36, p=0.006), creatinine (β=0.3, p=0.024) and serum MPO level (β=0.41, p=0.009) were significant determinants of H-FABP levels.
We found that MPO is one of the independent determinants of serum H-FABP levels. Our results suggest that increased MPO levels may contribute to ongoing myocardial damage in patients with chronic HF.